Latest Period
Q4 2025
Security Snapshot
Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) Institutional Ownership
CUSIP: 98943L107
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
85
Shares (Excl. Options)
40,517,312
Price
$1.35
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock,$0.001 par value per share
- Symbol
- ZNTL on Nasdaq
- Shares outstanding
- 72,096,078
- Price per share
- $6.61
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 40,517,312
- Total reported value
- $54,747,323
- % of total 13F portfolios
- 0%
- Share change
- -12,802,365
- Value change
- -$20,028,376
- Number of holders
- 85
- Price from insider filings
- $6.61
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share is tracked under CUSIP 98943L107.
- 85 institutions reported positions in Q4 2025.
- 9 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 85 to 20 between Q4 2025 and Q1 2026.
- Reported value moved from $54,747,323 to $10,875,282.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 85 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 98943L107?
CUSIP 98943L107 identifies ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 98943L107:
Significant Owners of Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| WALTERS GROUP | 20% | $20,264,960 | 13,509,973 | Walters William T | 31 Dec 2025 | |||
| Walters William T | 9.9% | +8.9% | $10,081,500 | +$786,500 | 7,050,000 | +8.5% | Walters William T | 29 Jan 2025 |
| 5AM Opportunities II (GP), LLC | 6.4% | $7,257,856 | 4,838,571 | Andrew J. Schwab | 18 Dec 2025 | |||
| BARCLAYS PLC | 5.3% | $5,800,588 | 3,841,449 | Barclays PLC | 30 Sep 2025 | |||
| Squadron Capital Management LLC | 5.1% | $9,376,095 | 3,676,900 | Squadron Master Fund LP | 24 Feb 2026 | |||
| VANGUARD GROUP INC | 4.6% | $4,677,873 | 3,271,240 | The Vanguard Group | 31 Dec 2024 | |||
| BlackRock, Inc. | 2.2% | $1,952,121 | 1,613,323 | BlackRock, Inc. | 30 Jun 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 1.3% | -80% | $1,272,555 | -$4,059,076 | 902,521 | -76% | Millennium Management LLC | 30 Sep 2025 |
| FMR LLC | 0.2% | $251,484 | 175,863 | FMR LLC | 29 Nov 2024 |
As of 31 Dec 2025, 85 institutional investors reported holding 40,517,312 shares of Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL). This represents 56% of the company’s total 72,096,078 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) together control 48% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| 5AM Venture Management, LLC | 5.5% | 3,947,913 | +706% | 1.7% | $5,329,683 |
| RENAISSANCE TECHNOLOGIES LLC | 4% | 2,883,745 | +24% | 0.01% | $3,893,056 |
| VANGUARD GROUP INC | 4% | 2,855,590 | -1.7% | 0% | $3,855,047 |
| ACADIAN ASSET MANAGEMENT LLC | 4% | 2,849,294 | +0.15% | 0.01% | $3,839,000 |
| CITADEL ADVISORS LLC | 2.7% | 1,964,255 | -5.4% | 0% | $2,651,744 |
| D. E. Shaw & Co., Inc. | 2.3% | 1,660,378 | +18% | 0% | $2,241,510 |
| TWO SIGMA ADVISERS, LP | 2.1% | 1,483,500 | +1.5% | 0% | $2,002,725 |
| TWO SIGMA INVESTMENTS, LP | 2% | 1,471,414 | +7.9% | 0% | $1,986,409 |
| Opaleye Management Inc. | 1.9% | 1,400,906 | +343% | 0.25% | $1,891,223 |
| BANK OF AMERICA CORP /DE/ | 1.9% | 1,367,254 | -12% | 0% | $1,845,793 |
| Decheng Capital LLC | 1.8% | 1,323,327 | 0% | 0.24% | $1,786,491 |
| Ishara Investments LP | 1.8% | 1,320,000 | 0% | 2.1% | $1,782,000 |
| BlackRock, Inc. | 1.7% | 1,249,968 | +0.04% | 0% | $1,687,457 |
| GSA CAPITAL PARTNERS LLP | 1.6% | 1,169,573 | +8.5% | 0.14% | $1,579,000 |
| PRIMECAP MANAGEMENT CO/CA/ | 1.3% | 957,420 | -0.54% | 0% | $1,292,517 |
| Pfizer Inc | 1.3% | 953,834 | 0% | 0.54% | $1,287,675 |
| MORGAN STANLEY | 1.1% | 803,654 | -43% | 0% | $1,084,932 |
| Connor, Clark & Lunn Investment Management Ltd. | 1.1% | 787,055 | +107% | 0% | $1,062,524 |
| UBS Group AG | 0.94% | 674,598 | +27% | 0% | $910,707 |
| MILLENNIUM MANAGEMENT LLC | 0.93% | 673,129 | -25% | 0% | $908,724 |
| Almitas Capital LLC | 0.85% | 610,073 | +33% | 0.18% | $823,599 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.82% | 589,105 | -0.02% | 0% | $795,720 |
| XTX Topco Ltd | 0.8% | 576,707 | +5.1% | 0.02% | $778,554 |
| BARCLAYS PLC | 0.79% | 568,443 | +252% | 0% | $767,398 |
| Woodline Partners LP | 0.74% | 530,582 | 0% | 0% | $716,286 |
Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 4,648,870 | $10,875,282 | -$2,348,285 | $2.34 | 20 |
| 2025 Q4 | 40,517,312 | $54,747,323 | -$20,028,376 | $1.35 | 85 |
| 2025 Q3 | 52,751,330 | $79,656,235 | -$3,936,309 | $1.51 | 96 |
| 2025 Q2 | 55,655,238 | $64,573,024 | -$4,209,380 | $1.16 | 115 |
| 2025 Q1 | 58,450,755 | $92,928,558 | -$20,527,901 | $1.59 | 131 |
| 2024 Q4 | 64,418,043 | $195,184,400 | -$24,736,255 | $3.03 | 141 |
| 2024 Q3 | 70,964,067 | $261,154,970 | -$21,635,153 | $3.68 | 133 |
| 2024 Q2 | 76,565,937 | $313,165,477 | -$54,359,485 | $4.09 | 142 |
| 2024 Q1 | 85,290,558 | $1,344,227,610 | +$67,005,140 | $15.76 | 140 |
| 2023 Q4 | 81,068,438 | $1,228,198,230 | -$21,970,408 | $15.15 | 118 |
| 2023 Q3 | 80,197,042 | $1,608,751,464 | -$51,643,382 | $20.06 | 136 |
| 2023 Q2 | 82,228,758 | $2,319,672,532 | +$442,954,370 | $28.21 | 131 |
| 2023 Q1 | 67,021,594 | $1,152,767,927 | +$44,945,526 | $17.20 | 108 |
| 2022 Q4 | 64,360,813 | $1,296,145,033 | +$105,231,060 | $20.14 | 106 |
| 2022 Q3 | 58,811,479 | $1,273,846,102 | -$54,003,564 | $21.66 | 116 |
| 2022 Q2 | 58,254,677 | $1,636,896,016 | +$359,446,058 | $28.10 | 115 |
| 2022 Q1 | 44,437,538 | $2,050,628,439 | +$49,057,461 | $46.14 | 123 |
| 2021 Q4 | 42,987,158 | $3,611,907,936 | +$90,022,119 | $84.06 | 134 |
| 2021 Q3 | 41,250,292 | $2,749,252,645 | +$115,288,600 | $66.64 | 114 |
| 2021 Q2 | 39,699,603 | $2,112,018,735 | +$205,833,024 | $53.20 | 117 |
| 2021 Q1 | 36,327,192 | $1,576,156,109 | -$55,960,381 | $43.39 | 93 |
| 2020 Q4 | 37,299,066 | $1,937,340,198 | +$309,645,949 | $51.94 | 104 |
| 2020 Q3 | 31,635,340 | $1,033,195,545 | +$169,604,096 | $32.69 | 65 |
| 2020 Q2 | 26,858,048 | $1,282,608,905 | +$1,282,608,902 | $48.02 | 61 |